Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study

Trials
Martin DugasCarsten Müller-Tidow

Abstract

The identification of suitable patients is a common problem in clinical trials that is especially evident in tertiary care hospitals. We developed and analysed a workflow, which uses routine data captured during patient care in a hospital information system (HIS), to identify potential trial subjects. Study nurses or physicians are notified automatically by email and verify eligibility. As a case study we implemented the system for acute myeloid leukemia (AML) trials in Münster. During a test period of 50 days 41 patients were identified by the system. 13 could be included as new trial patients, 7 were already included during earlier visits. According to review of paper records no AML trial patient was missed by the system. In addition, the hospital information system further allowed to preselect patients for specific trials based on their disease status and individual characteristics. Routine HIS data can be used to support patient recruitment for clinical trials by means of an automated notification workflow.

References

Jan 28, 2003·Annals of Emergency Medicine·Debra L WeinerGary R Fleisher
Oct 26, 2005·Archives of Internal Medicine·Peter J EmbiC Martin Harris

❮ Previous
Next ❯

Citations

Feb 16, 2011·BMC Medical Research Methodology·Stephanie HeinemannWolfgang Himmel
Feb 18, 2011·BMC Medical Informatics and Decision Making·Bernhard BreilMartin Dugas
Jul 6, 2014·Journal of Medical Internet Research·Felix Köpcke, Hans-Ulrich Prokosch
Sep 18, 2012·International Journal of Medical Informatics·D UrdaJ M Jerez
Jan 18, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Leyla MohseninejadTalitha Feenstra
Mar 17, 2010·Contemporary Clinical Trials·Lynne PenberthyBassam Dahman
Jan 1, 2011·Applied Clinical Informatics·E ChowD Morra
Mar 19, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L Carmi, J Zohar
Jul 14, 2016·Methods of Information in Medicine·Martin LöpprichPetra Knaup
Mar 20, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Brigitte KendallSteven K Hildemann
Mar 27, 2010·Clinical Trials : Journal of the Society for Clinical Trials·Martin DugasHans-Ulrich Prokosch
Jan 26, 2012·Clinical Trials : Journal of the Society for Clinical Trials·N Maritza DowlingCarey Gleason
Jul 17, 2020·Perspectives in Clinical Research·Nayan ChaudhariUrmila M Thatte
Feb 7, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Catherine C BeauharnaisDeborah J Wexler

❮ Previous
Next ❯

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.